GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Interpace Biosciences Inc (STU:PF42) » Definitions » Cyclically Adjusted Revenue per Share

Interpace Biosciences (STU:PF42) Cyclically Adjusted Revenue per Share : €-2.75 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Interpace Biosciences Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Interpace Biosciences's adjusted revenue per share for the three months ended in Mar. 2024 was €2.156. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €-2.75 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Interpace Biosciences's average Cyclically Adjusted Revenue Growth Rate was -102.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -58.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -41.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -26.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Interpace Biosciences was -0.40% per year. The lowest was -58.40% per year. And the median was -15.70% per year.

As of today (2024-06-06), Interpace Biosciences's current stock price is €1.32. Interpace Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €-2.75. Interpace Biosciences's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Interpace Biosciences was 0.42. The lowest was 0.01. And the median was 0.02.


Interpace Biosciences Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Interpace Biosciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Interpace Biosciences Cyclically Adjusted Revenue per Share Chart

Interpace Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 400.96 288.20 213.07 90.30 21.98

Interpace Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.46 70.09 - 21.98 -2.75

Competitive Comparison of Interpace Biosciences's Cyclically Adjusted Revenue per Share

For the Diagnostics & Research subindustry, Interpace Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Interpace Biosciences's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Interpace Biosciences's Cyclically Adjusted PS Ratio falls into.



Interpace Biosciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Interpace Biosciences's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.156/131.7762*131.7762
=2.156

Current CPI (Mar. 2024) = 131.7762.

Interpace Biosciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 153.168 100.560 200.716
201409 147.201 100.428 193.150
201412 -487.852 99.070 -648.910
201503 13.040 99.621 17.249
201506 13.204 100.684 17.282
201509 14.223 100.392 18.669
201512 14.663 99.792 19.363
201603 15.309 100.470 20.079
201606 17.665 101.688 22.892
201609 16.236 101.861 21.004
201612 15.914 101.863 20.587
201703 7.406 102.862 9.488
201706 3.552 103.349 4.529
201709 1.600 104.136 2.025
201712 1.327 104.011 1.681
201803 1.400 105.290 1.752
201806 1.686 106.317 2.090
201809 1.747 106.507 2.161
201812 1.791 105.998 2.227
201903 1.513 107.251 1.859
201906 1.455 108.070 1.774
201909 1.836 108.329 2.233
201912 0.990 108.420 1.203
202003 2.047 108.902 2.477
202006 1.199 108.767 1.453
202009 1.734 109.815 2.081
202012 1.962 109.897 2.353
202103 2.020 111.754 2.382
202106 2.257 114.631 2.595
202109 1.644 115.734 1.872
202112 1.928 117.630 2.160
202203 1.710 121.301 1.858
202206 1.654 125.017 1.743
202209 1.950 125.227 2.052
202212 1.841 125.222 1.937
202303 2.130 127.348 2.204
202306 2.358 128.729 2.414
202309 0.000 129.860 0.000
202312 2.148 129.419 2.187
202403 2.156 131.776 2.156

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Interpace Biosciences  (STU:PF42) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Interpace Biosciences was 0.42. The lowest was 0.01. And the median was 0.02.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Interpace Biosciences Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Interpace Biosciences's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Interpace Biosciences (STU:PF42) Business Description

Traded in Other Exchanges
Address
300 Interpace Parkway, Morris Corporate Center 1, Building C, Parsippany, NJ, USA, 07054
Interpace Biosciences Inc is engaged in the life sciences industry. It provides molecular diagnostics, bioinformatics, and pathology services for the evaluation of the risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first-line assays principally focused on the early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology. It operates under one segment which is the business of developing and selling diagnostic clinical services.

Interpace Biosciences (STU:PF42) Headlines

No Headlines